Immuneering Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections and auditor ratification, with both proposals approved. No questions were raised by stockholders, and final vote results will be published in a Form 8-K filing.
-
Phase II-A data for atebimetinib plus modified gemcitabine nab-paclitaxel in first-line pancreatic cancer show a median overall survival of 17.3 months with favorable tolerability and high rates of weight stability. The phase III MAPKeeper 301 trial is now recruiting, and the company is financially positioned to fund operations into 2029.
-
Atebimetinib demonstrated a 64% 12-month overall survival in first-line pancreatic cancer, with robust tolerability and unique mechanisms supporting both efficacy and quality of life. The pivotal phase III trial is set to begin dosing mid-year, with a top-line OS readout expected in about two years.
-
Deep Cyclic Inhibitors, led by atebimetinib, show promising survival and tolerability in First-Line pancreatic cancer, with 64% 12-month survival and minimal added toxicity. A pivotal phase III trial is launching, and combination studies in lung cancer are planned.
-
Atebimetinib, a novel Deep Cyclic Inhibitor, demonstrated 64% 12-month survival in first-line pancreatic cancer, nearly doubling standard benchmarks. A global Phase III trial will begin mid-year, with expanded cohort data expected in 2026, and strong enthusiasm from investigators and KOLs.
-
Atebumetanib plus chemotherapy achieved a 64% 12-month overall survival in first-line pancreatic cancer, nearly doubling the standard of care, with strong durability, favorable safety, and significant quality of life improvements. The upcoming Phase 3 trial will further evaluate these benefits.
Fiscal Year 2025
-
Extraordinary survival and tolerability data were presented for a novel deep cyclic inhibitor in first-line pancreatic cancer, with robust results in an older patient population and plans for a pivotal Phase 3 trial in 2026. Recent financing extends runway into 2029.
-
Exceptional nine-month overall survival of 86% was reported for atebimetinib plus modified gemcitabine nab-paclitaxel in first-line pancreatic cancer, with strong tolerability and rare complete responses observed. Cash position improved to $227.6 million, funding operations into 2029.
-
A phase II-A trial of atobemetinib plus modified chemotherapy in first-line pancreatic cancer showed a 94% six-month overall survival, 72% progression-free survival, and strong tolerability with minimal serious adverse events. The unique deep cyclic inhibition mechanism supports durable responses and broad potential across cancers.
-
A novel approach using deep cyclic inhibition aims to make cancer a chronic, manageable disease by maximizing durability and tolerability. Early clinical data for IMM-1104 in pancreatic cancer show durable responses, high tolerability, and promising combination results.
-
The session highlighted strong clinical progress for 104, a novel MEK inhibitor, with encouraging efficacy and tolerability in pancreatic cancer, especially in combination with standard chemotherapy. A pivotal study is being planned, with a major data update expected in Q2.
-
IMM-1-104 shows promising efficacy and tolerability in first-line pancreatic cancer, with response rates nearly double standard care and a strong safety profile. Planned phase 3 trials and new collaborations, including with Regeneron, aim to expand its use across multiple cancer types.
-
IMM-1-104 in phase IIA pancreatic cancer arms showed a 43% ORR and 86% DCR in first-line combination, with strong tolerability and no serious drug-related adverse events. Plans are underway for a pivotal phase III trial and further expansion into other cancers.
Fiscal Year 2024
-
The company is advancing a novel deep cyclic inhibition approach targeting the MAP kinase pathway, with early phase IIA data in pancreatic cancer showing rare complete and partial responses and a strong safety profile. Multiple expansion arms are underway, with further data and pipeline updates expected by year-end.
-
Initial Phase II-A data show a 40% response rate and 80% disease control in first-line pancreatic cancer patients treated with IMM-1-104 plus modified chemotherapy, with strong tolerability and a rare complete response observed. All patients remain on treatment, and further updates are planned.
-
IMM-1-104 demonstrated strong tolerability and broad MAP kinase pathway inhibition in phase I, with encouraging early efficacy in late-line pancreatic cancer. Multiple phase II-A arms, including combination therapies, are underway with data expected this year. Cash reserves support operations into H2 2025.
-
IMM-1-104, using Deep Cyclic Inhibition, showed strong safety and promising activity in late-line cancer patients, with no RAS-mediated resistance and notable tumor shrinkage. Phase 2a trials, including combination and monotherapy arms across multiple tumor types, are underway with initial data expected in 2024.